- Home
- TWN vs LRMR Comparison
TWN vs LRMR Comparison
Compare TWN & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWN
- LRMR
- Stock Information
- Founded
- TWN 1986
- LRMR N/A
- Country
- TWN Hong Kong
- LRMR United States
- Employees
- TWN N/A
- LRMR N/A
- Industry
- TWN Trusts Except Educational Religious and Charitable
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- TWN Finance
- LRMR Health Care
- Exchange
- TWN Nasdaq
- LRMR Nasdaq
- Market Cap
- TWN 346.7M
- LRMR 360.3M
- IPO Year
- TWN N/A
- LRMR N/A
- Fundamental
- Price
- TWN $58.10
- LRMR $4.31
- Analyst Decision
- TWN
- LRMR Strong Buy
- Analyst Count
- TWN 0
- LRMR 7
- Target Price
- TWN N/A
- LRMR $16.71
- AVG Volume (30 Days)
- TWN 20.1K
- LRMR 3.1M
- Earning Date
- TWN 01-01-0001
- LRMR 11-14-2025
- Dividend Yield
- TWN 1.10%
- LRMR N/A
- EPS Growth
- TWN N/A
- LRMR N/A
- EPS
- TWN N/A
- LRMR N/A
- Revenue
- TWN N/A
- LRMR N/A
- Revenue This Year
- TWN N/A
- LRMR N/A
- Revenue Next Year
- TWN N/A
- LRMR N/A
- P/E Ratio
- TWN N/A
- LRMR N/A
- Revenue Growth
- TWN N/A
- LRMR N/A
- 52 Week Low
- TWN $25.22
- LRMR $1.61
- 52 Week High
- TWN $41.51
- LRMR $9.50
- Technical
- Relative Strength Index (RSI)
- TWN 71.02
- LRMR 51.28
- Support Level
- TWN $56.10
- LRMR $3.87
- Resistance Level
- TWN $57.00
- LRMR $4.46
- Average True Range (ATR)
- TWN 1.80
- LRMR 0.30
- MACD
- TWN 0.09
- LRMR -0.01
- Stochastic Oscillator
- TWN 90.06
- LRMR 65.93
About TWN Taiwan Fund Inc. (The)
Taiwan Fund Inc is a diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment predominantly in equity securities listed in Taiwan stock exchange and the Republic of China. In selecting the companies for investments fund's portfolio managers will consider overall growth prospects, competitive position in the respective industry technology, research, and development, productivity, profit margins, return on investment, capital resources, government regulation, management and other factors.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.